Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Open, Dose-escalation and Expansion Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors

NCT06468358 is registered in ClinicalTrials.gov with L & L Bio Co., Ltd., Ningbo, China as lead sponsor.

NCT NCT06468358
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06468358 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Open, Dose-escalation and Expansion Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors
Lead sponsor
L & L Bio Co., Ltd., Ningbo, China
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 19, 2024
Completion date
December 30, 2027
Enrollment
194 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor